殷曉煜
殷曉煜
職稱:二級教授/一級主任醫(yī)師
科室:膽胰外科
學(xué)位/學(xué)歷:博士/研究生
導(dǎo)師資格:博士生導(dǎo)師
職務(wù):副院長、膽胰外科學(xué)科帶頭人
簡介:1,、具有十分豐富的胰腺,、膽道及肝臟各種疾病、疑難復(fù)雜病的診治經(jīng)驗(yàn),。2,、擅長機(jī)器人、腹腔鏡微創(chuàng)手術(shù)治療各種肝膽胰疾病,,開拓性地開展機(jī)器人胰十二指腸切除術(shù),、胰腺中段切除術(shù)、肝門部膽管癌根治術(shù),、肝中葉切除術(shù),、右半肝切除術(shù)等各種高難度手術(shù);不斷突破手術(shù)“禁區(qū)”,,已成功為多例85歲以上超高齡患者實(shí)施機(jī)器人胰十二指腸切除術(shù),,至今已完成1000多例機(jī)器人肝膽胰手術(shù),位居國內(nèi)先進(jìn),、華南地區(qū)領(lǐng)先的地位,,是國內(nèi)該領(lǐng)域的領(lǐng)軍人物之一;③擅長胰腺癌,、胰腺神經(jīng)內(nèi)分泌腫瘤,、膽管癌、肝癌等以手術(shù)為主的綜合治療,。
出診時間
專家門診
周一
Mon
周二
Tue
周三
Wed
周四
Thur
周五
Fri
周六
Sat
周日
Sun
上午
AM
下午
PM
出診時間以實(shí)際為準(zhǔn)

一,、研究方向:

1、胰腺惡性腫瘤,、神經(jīng)內(nèi)分泌腫瘤的臨床與基礎(chǔ)研究,;

2、膽道惡性腫瘤臨床與基礎(chǔ)研究,;

3,、肝臟惡性腫瘤臨床與基礎(chǔ)研究,;

至今已主持5項(xiàng)國家自然科學(xué)基金、近10項(xiàng)省部級基金資助的課題研究,,取得了豐碩的成果,。

 

三、社會兼職:

1,、中華醫(yī)學(xué)會外科學(xué)分會第十八屆委員會胰腺外科學(xué)組委員,;

2、中國抗癌協(xié)會神經(jīng)內(nèi)分泌腫瘤專業(yè)委員會副主任委員,;

3,、中國抗癌協(xié)會膽道腫瘤專業(yè)委員會第四屆委員會常委;

4,、中國醫(yī)師協(xié)會胰腺病學(xué)專業(yè)委員會第二屆委員會常務(wù)委員,;

5、中國醫(yī)師協(xié)會外科醫(yī)師分會機(jī)器人外科專家工作組副組長,;

6,、中國醫(yī)藥教育協(xié)會醫(yī)療機(jī)器人發(fā)展促進(jìn)分會副主任委員,;

7,、中國研究型醫(yī)院學(xué)會胰腺病學(xué)委員會常委;

8,、中國研究型醫(yī)院學(xué)會術(shù)后快速康復(fù)專業(yè)委員會常委,;

9、中國研究型醫(yī)院學(xué)會智能醫(yī)學(xué)專業(yè)委員會常委,;

10,、國際肝膽胰協(xié)會中國分會膽道腫瘤專業(yè)委員會副主任委員

11、廣東省醫(yī)學(xué)會外科學(xué)分會副主任委員

12,、廣東省醫(yī)學(xué)會肝膽胰外科學(xué)分會常務(wù)委員,;

13、廣東省醫(yī)師協(xié)會胰腺病學(xué)專業(yè)委員會副主任委員,;

14,、廣東省醫(yī)療行業(yè)協(xié)會肝膽胰外科管理分會主任委員;

15,、廣東省臨床醫(yī)學(xué)學(xué)會肝膽胰外科專業(yè)委員會主任委員,;

16、廣東省抗癌協(xié)會胰腺癌專業(yè)委員會副主任委員,;

17,、廣東省抗癌協(xié)會膽道腫瘤專業(yè)委員會主任委員;

18,、Gastroenterology Report》,、《中華肝膽外科雜志》,、《中華消化外科雜志》、《中華胰腺病學(xué)雜志》,、《中華普通外科文獻(xiàn)雜志》電子版等多家雜志編委,。

 

四、發(fā)表論文:

目前已在“Advanced Science (IF=14.3)”,、“ACS Nano (IF=15.3)” ,、 “Cancer Communications (IF=20.1)”“Cell Death and Differentiation (IF=13.7)”,、“Molecular Therapy (IF=12.1)”,、“Cancer Letters (IF=9.1”“Oncogene (IF=6.9)”,、“Int J Biol Sci (IF=8.2)”,、“Clin Trans Med (IF=7.9)” “Applied Materials Today (IF=7.2)”,、“Br J Surg (IF=8.6)”SCI雜志,、及中華外科雜志中華消化外科雜志,、中華肝膽外科雜志,、中國實(shí)用外科雜志等國內(nèi)核心期刊發(fā)表第一作者和(或)通訊作者論文140多篇。近期發(fā)表的部分論文如下:

  1. Shi YH, Liu ZD, Ma MJ, Zhao GY, Zhu YQ, Wang JQ, Yu YY, Huang XT, Ye JY, Li FX, Wang XY, Xu QC, Yin XY. Platelet-Derived Growth Factor C Facilitates Malignant Behavior of Pancreatic Ductal Adenocarcinoma by Regulating SREBP1 Mediated Lipid Metabolism. Adv Sci (Weinh). 2024 Sep 3:e2407069. doi: 10.1002/advs.202407069. Epub ahead of print. PMID: 39225567. (通訊作者)
  2. Zhu YQ, Huang Y, Shi YH, Huang CS, Zhao GY, Liu ZD, Ma MJ, Ye JY, Xu X, Liu Q, Huang XT, Wang JQ, Xu QC, Yin XY. Epigenetic Activation of the CMTM6-IGF2BP1-EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Adv Sci (Weinh). 2024 Nov 3:e2406714. doi: 10.1002/advs.202406714. Epub ahead of print. PMID: 39488785. (通訊作者)
  3. Ma MJ, Shi YH, Liu ZD, Zhu YQ, Zhao GY, Ye JY, Li FX, Huang XT, Wang XY, Wang JQ, Xu QC, Yin XY. N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance. Oncogene. 2024 Jun 24. (通訊作者)
  4. Liu ZD, Shi YH, Xu QC, Zhao GY, Zhu YQ, Li FX, Ma MJ, Ye JY, Huang XT, Wang XY, Xu X, Wang JQ, Zhao W, Yin XY. CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy. Cancer Lett. 2024 Mar 31;585:216640. doi: 10.1016/j.canlet.2024.216640. Epub 2024 Jan 28. PMID: 38290659. (通訊作者)
  5. Huang XT, Qu XF, Zhou JW, Cai JP, Xie JZ, Chen W, Chen LH, Yin XY. Robotic-assisted organ-preserving or parenchymal-sparing pancreatectomy in pancreatic benign or low-grade malignant tumors: a single institute’s experience. J Robotic Surgery. 2024:18:1.(通訊作者)
  6. Wang XY, Huang XT, Cai JP, Li B, Chen W, Huang CS, Yin XY. Robotic-Assisted Versus Open Hemi-Hepatectomy: A Propensity Score Analysis. J Surg Res 2024; https://doi.org/10.1016/j.jss.2024.09.001,。(通訊作者)
  7. Wu X, Li JH, Xu L, Li YX, Zhu XX, Wang XY, Wu X, Zhao W, Ni X, Yin XY. SUMO specific peptidase 3 halts pancreatic ductal adenocarcinoma metastasis via deSUMOylating DKC1. Cell Death Differ. 2023 May 15. doi: 10.1038/s41418-023-01175-4. (通訊作者)
  8. Huang XT, Xie JZ, Cai JP, Chen W, Chen LH, Yin XY. Learning curve of robotic-assisted splenic vessel-preserving spleen-preserving distal pancreatectomy by one single surgeon: a retrospective cohort study. BMC Surgery 2023; 23:382. (通訊作者)
  9. Huang XT, Cai JP, Yin XY. Robotic-assisted hepatopancreatoduodenectomy and resection of pancreatic tail for one multiple endocrine neoplasia type 1 secreting multiple hormones. HepatoBiliary Surgery and Nutrition 2023; doi: 10.21037/hbsn-23-315. (通訊作者)
  10. Huang XT, Wang XY, Xie JZ, Cai JP, Chen W, Chen LH, Yin XY. Learning curves of resection and reconstruction procedures in robotic-assisted pancreatoduodenectomy by a single surgeon: a retrospective cohort study of 160 consecutive cases. Gastroenterol Rep (Oxf). 2023;11:goad042.doi: 10.1093/gastro/goad042.eCollection 2023. (通訊作者)
  11. Ye JY, Fang P, Peng ZP, Huang XT, Xie JZ, Yin XY. radiomics-based interpretable model to predict the pathological grade of pancreatic neuroendocrine tumors. European Radiology. 2023; https://doi.org/10.1007/s00330-023-10186-1(通訊作者)
  12. Huang XT, Xie JZ, Cai JP, Chen W, Chen LH, Liang LJ, Yin XY. Evaluation of the short-term outcomes of robotic-assisted radical resection for perihilar cholangiocarcinoma: a propensity-scored matching analysis. Gastroenterol Report 2023,11,goad018. (通訊作者)
  13. Shi YH, Xu QC, Zhu YQ, Liu ZD, Zhao GY, Liu Q, Wang XY, Wang JQ, Xu X, Su Q, Lai JM, Huang CS, Yin XY. Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer. Mol Ther. 2022 Nov 15:S1525-0016(22)00662-1.(通訊作者)
  14. Huang CS, Xu QC, Dai C, Wang L, Tien YC, Li F, Su Q, Huang XT, Wu J, Zhao W, Yin XY. Nanomaterial-Facilitated Cyclin-Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction. ACS Nano. 2021 Sep 28;15(9):14744-14755. (通訊作者)
  15. Xu QC, Tien YC, Shi YH, Chen S, Zhu YQ, Huang XT, Huang CS, Zhao W, Yin XY. METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m6A-YTHDF2-dependent manner. Oncogene. 2022 Mar;41(11):1622-1633.(通訊作者) 
  16. Huang XT, Li JH, Zhu XX, Huang CS, Gao ZX, Xu QC, Zhao W, Yin XY. HNRNPC impedes m6A-dependent anti-metastatic alternative splicing events in pancreatic ductal adenocarcinoma. Cancer Lett. 2021 Oct 10;518:196-206.(通訊作者)
  17. Li YX, Zhu XX, Wu X, Li JH, Ni XH, Li SJ, Zhao W, Yin XY. ACLP promotes activation of cancer-associated fibroblasts and tumor metastasis via ACLP-PPARγ-ACLP feedback loop in pancreatic cancer. Cancer Lett. 2022 Sep 28;544:215802. (通訊作者)
  18. Xu QC, Tien YC, Shi YH, Chen SY, Zhu YQ, Huang XT, Huang CS, Zhao W, Yin XY. METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m6A-YTHDF2-dependent manner. Oncogene 2022; doi:10.1038/s41388-022-02185-1.(通訊作者)
  19.  Huang CS, Zhu YQ, Xu QC, Chen SY, Huang Y, Zhao GY, Ni XH, Liu B, Zhao W, Yin XY. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitizes cisplatin treatment by increasing CDKN1B mRNA degradation Running title YTHDF2 drives ICC progression and chemo-resistance. Clin. Transl. Med. 2022;12:e848.(通訊作者)
  20. Li YX, Zhu XX, Wu X, Li JH, Ni XH, Li SJ, Zhao W, Yin XY. ACLP promotes activation of cancer-associated fibroblasts and tumor metastasis via ACLP-PPARγ-ACLP feedback loop in pancreatic cancer. Cancer Letter 2022. https://doi.org/10.1016/j.canlet.2022.215802.(通訊作者)
  21.  Ni X; Wu X; Zhu XX; Li JH; Yin XY; Lu L. Carabin Deficiency Aggravates Hepatic Ischemia-Reperfusion Injury Through Promoting Neutrophil Trafficking via Ras and Calcineurin Signaling. Front Immunol.2022;13;773291.(共同通訊作者)
  22. Huang CS, Xu QC, Dai CL, Wang LY, Tien YC, Li FX, Su Q, Huang XT, Wu J, Zhao W, Yin XY. Nanomaterial-Facilitated Cyclin-Dependent Kinase7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction. ACS Nano. 2021;15(9):14744-14755. (通訊作者)
  23. Huang XT, Cai JP, Chen W, Huang CS, Li JH. Gang TT, Liang LJ, Yin XY. Establishment and validation of a nomogram for predicting overall survival of node negative perihilar cholangiocarcinoma. Asian J Surg. 2022;45:712-717. (通訊作者)
  24. Cai JP, Chen W, Chen LH, Wang XY, Lai JM, Yin XY. Comparison between robotic-assisted and laparoscopic left hemi-hepatectomy. Asian J Surg 2022;45(1):265-268. (通訊作者)
  25. Huang XT, Li JH, Zhu XX, Huang CS, Gao ZX, Xu QC, Zhao W, Yin XY. HNRNPC impedes m6 A-dependent anti-metastatic alternative splicing events in pancreatic ductal adenocarcinoma. Cancer Letter. 2021;518:196–206. (通訊作者)
  26. Xu QC, Wang LY, Tong T, Huang XT, Huang CS, Li FX, Su Q, Tien YC, Wu J, Zhao W, Yin XY. Efficient Delivery of BRD4 Inhibitor by Glutathione-sensitive Nanoparticle to Suppress Gallbladder Cancer Through Inhibiting NF-κB Signaling. Applied Material Today 2020;21:100849. (通訊作者)
  27. Wang XY, Cai JP, Song LL, Huang CS, Chen W, Huang XT, Chen SF, Liu XY, Yin XY. Identification of Genomic Alterations in Sporadic Pancreatic Neurogenic Tumors. Pancreas 2020;49:1393-1397. (通訊作者)
  28. Huang XT, Huang CS, Liu C, Chen W, Cai JP, Cheng H, Jiang XX, Liang LJ, Yu XJ, Yin XY. Development and Validation of a New Nomogram for Predicting Clinically Relevant Postoperative Pancreatic Fistula After Pancreatoduodenectomy. World J Surg 2021, 45, 261-269. (通訊作者)
  29. Huang XT, Huang CS, Li JH, Chen W, Gan TT, Wang XY, Liang LJ, Yin XY. Evaluating the adequacy of nodal status in node-negative gallbladder cancer with T1b-T2 stages: use of nodal staging score. HPB (Oxford) 2021;23(5):795-801.(通訊作者)
  30. Huang CS, You X, Dai C, Xu QC, Li F, Wang L, Huang XT, Wang JQ, Li SJ, Gao Z, Wu J, Yin XY, Zhao W. Targeting Super-Enhancers via Nanoparticle-Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic Ductal Adenocarcinoma. Adv. Sci. 2020, 7(7):1902926.(共同通訊作者)
  31. Chen HD, Huang CS, Xu QC, Li FX, Huang XT, Wang JQ, Li SJ, Zhao W, Yin XY. Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic Cholangiocarcinoma. Int J Biol Sci. 2020;16(7):1207-1217.(通訊作者)
  32. Wang JQ, Wang LY, Li SJ, Tong T, Wang L, Huang CS, Xu QC, Huang XT, Li JH, Wu J, Zhao W, Yin XY. Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma therapy. Nanoscale. 2020;12(29):15767-15774.(通訊作者)
  33. Huang XT, Huang CS, Li JH, Xu QC, Yin XY. Use of nodal staging score in evaluating the accuracy of pathologic nodal status in node-negative ampullary carcinoma. J Gastrointestinal Surg. 2021;25:1001-1009.(通訊作者)
  34. Zhu XX, Li JH, Cai JP, Hou X, Huang CS, Huang XT, Wang JQ, Li SJ, Xu QC, Yin XY. EYA4 inhibits hepatocellular carcinoma by repressing MYCBP by dephosphorylating β-catenin at Ser552. Cancer Sci. 2019;110(10):3110-3121.(通訊作者)
  35. Huang XT, Huang CS, Chen W, Cai JP, Gan TT, Zhao Y, Liu Q, Liang LJ, Yin XY. Development and validation of a nomogram for predicting overall survival of node-negative ampullary carcinoma. J Surg Oncol. 2020;121(1):518–523.(通訊作者)
  36. Gao SW, Huang CS, Huang XT, Chen LH, Chen W, Cai JP, Yin XY. Ki-67 Index of 5% is Better Than 2% in Stratifying G1 and G2 of WHO Grading System in Pancreatic Neuroendocrine Tumors. Pancreas 2019; 48(6):795-798. (通訊作者)
  37. Huang XT, Chen LH, Huang CS, Li JH, Cai JP, Chen W, Yin XY. Establishment of a Nomogram by Integrating Molecular Markers and Tumor-Node-Metastasis Staging System for Predicting the Prognosis of Hepatocellular Carcinoma. Dig Surg. 2019;36(5):426-432.(通訊作者)
  38. 黃錫泰 謝錦釗 蔡建鵬 許瓊聰 黃晨松 陳流華 陳偉 殷曉煜,。單一術(shù)者機(jī)器人輔助胰十二指腸切除術(shù)的近期療效分析。中華消化外科雜志,,2024,;23(4):596-600.
  39. 殷曉煜。膽囊管癌的臨床特征及治療,。中國實(shí)用外科雜志,。2023;43(11):56-58.
  40. 殷曉煜.機(jī)器人輔助肝門部膽管癌根治術(shù)的應(yīng)用現(xiàn)狀,、優(yōu)勢及局限性.中華腔鏡外科雜志(電子版).2022;15(2):69-72.
  41. 蔡建鵬,,陳偉,王曦域,,陳流華,,殷曉煜。機(jī)器人輔助胰十二指腸切除術(shù)在高齡患者的應(yīng)用,。中華腔鏡外科雜志,。2021;14(1):10-14. (通訊作者)
  42. 陳流華,,黃錫泰,,陳偉,,賴佳明,梁力建,,殷曉煜,。全尾狀葉切除在肝門部膽管癌根治術(shù)中的應(yīng)用。中華肝臟外科手術(shù)學(xué)雜志,。2021,;10(6):559-563。(通訊作者)
  43. 黃錫泰,、蔡建鵬,、陳偉、房鵬,,陳流華,,殷曉煜。機(jī)器人輔助保留脾臟遠(yuǎn)端胰腺切除術(shù)圍手術(shù)期指標(biāo)回顧性研究,。中國實(shí)用外科雜志,。2021;41(12):1407-1422. (通訊作者)
  44. 黃晨松,,鐘記華,,陳偉,蔡建鵬,,賴佳明,,梁力建,殷曉煜,。不同類型胰腺囊性腫瘤的診斷與治療。中華消化外科雜志,。2020,;19(12):1-7. (通訊作者)

 

五、專著:

  1. Yin XY. Diagnosis. In: Lau WY (ed). Hilar cholangiocarcinoma. Springer Science Business Media Dordrecht & People’s Medical Publishing House. 2013:91-98.